Genenta Science (NASDAQ:GNTA) Trading 7.4% Higher – Time to Buy?

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) shares traded up 7.4% during mid-day trading on Wednesday . The stock traded as high as $4.50 and last traded at $3.78. 34,951 shares changed hands during mid-day trading, an increase of 500% from the average session volume of 5,830 shares. The stock had previously closed at $3.52.

Genenta Science Stock Up 7.4%

The firm has a 50 day simple moving average of $3.61 and a 200-day simple moving average of $3.87.

Hedge Funds Weigh In On Genenta Science

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in Genenta Science in the fourth quarter valued at about $46,000. Algebris UK Ltd boosted its holdings in Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company’s stock worth $368,000 after acquiring an additional 55,000 shares in the last quarter. Finally, Allianz SE boosted its holdings in Genenta Science by 126.2% in the first quarter. Allianz SE now owns 233,550 shares of the company’s stock worth $927,000 after acquiring an additional 130,300 shares in the last quarter. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.